Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991 Apr;145(4):738-40.
doi: 10.1016/s0022-5347(17)38439-2.

Prospective Randomized Comparison of Intravesical With Percutaneous Bacillus Calmette-Guerin Versus Intravesical Bacillus Calmette-Guerin in Superficial Bladder Cancer

Affiliations
Clinical Trial

Prospective Randomized Comparison of Intravesical With Percutaneous Bacillus Calmette-Guerin Versus Intravesical Bacillus Calmette-Guerin in Superficial Bladder Cancer

D L Lamm et al. J Urol. .

Abstract

Conflicting reports of the necessity for percutaneous bacillus Calmette-Guerin (BCG) administration with intravesical BCG prompted us to evaluate its benefit in a randomized prospective comparison of intravesical versus intravesical with percutaneous BCG therapy. Intravesical Tice BCG was given in a dose of 50 mg. with or without percutaneous BCG weekly for 6 weeks, at 8, 10 and 12 weeks, at 6 months and every 6 months thereafter. Tumor recurrence was documented in 13 of 30 patients (43%) receiving only intravesical BCG and in 15 of 36 patients (42%) receiving intravesical plus percutaneous BCG. The addition of percutaneous BCG to intravesical therapy did not increase treatment efficacy in this study.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

Publication types

Feedback